4523

Eisai Co.,Ltd.

エーザイ

Industry
Pharmaceutical
Market
Prime
Accounting standards
IFRS
Consolidation basis
Consolidated

Key metrics

Revenue(million JPY)

Mar 2021
645,942
Mar 2022
756,226
Mar 2023
744,402
Mar 2024
741,751
Mar 2025
789,400

Operating profit(million JPY)

Mar 2021
51,766
Mar 2022
53,750
Mar 2023
40,040
Mar 2024
53,408
Mar 2025
54,378

Operating profit margin(%)

Mar 2021
8.01
Mar 2022
7.11
Mar 2023
5.38
Mar 2024
7.2
Mar 2025
6.89

Profit before tax(million JPY)

Mar 2021
52,551
Mar 2022
54,458
Mar 2023
45,012
Mar 2024
61,823
Mar 2025
61,065

Profit(million JPY)

Mar 2021
42,119
Mar 2022
47,954
Mar 2023
55,432
Mar 2024
42,406
Mar 2025
46,432

Total assets(million JPY)

Mar 2021
1,090,009
Mar 2022
1,239,315
Mar 2023
1,263,350
Mar 2024
1,393,799
Mar 2025
1,386,547

Cash and cash equivalents(million JPY)

Mar 2021
248,740
Mar 2022
309,633
Mar 2023
267,350
Mar 2024
304,678
Mar 2025
265,561

Cash flows from operating activities(million JPY)

Mar 2021
73,853
Mar 2022
117,590
Mar 2023
-1,772
Mar 2024
55,993
Mar 2025
30,117

Cash flows from investing activities(million JPY)

Mar 2021
-36,873
Mar 2022
-28,848
Mar 2023
-22,723
Mar 2024
-25,321
Mar 2025
-10,097

Cash flows from financing activities(million JPY)

Mar 2021
-55,908
Mar 2022
-48,967
Mar 2023
-24,522
Mar 2024
-22,720
Mar 2025
-57,809

Return on equity(%)

Mar 2021
6.1
Mar 2022
6.6
Mar 2023
7.2
Mar 2024
5.1
Mar 2025
5.4

Equity ratio(%)

Mar 2021
64.5
Mar 2022
60.4
Mar 2023
63.3
Mar 2024
62.8
Mar 2025
60.7

Earnings per share(JPY per share)

Mar 2021
146.95
Mar 2022
167.27
Mar 2023
193.31
Mar 2024
147.86
Mar 2025
163.76

Net assets per share(JPY per share)

Mar 2021
2,452.97
Mar 2022
2,611.82
Mar 2023
2,789.32
Mar 2024
3,052.99
Mar 2025
2,984.93

Dividend per share(JPY per share)

Mar 2021
160
Mar 2022
160
Mar 2023
160
Mar 2024
160
Mar 2025
160

Payout ratio(%)

Mar 2021
108.88
Mar 2022
95.65
Mar 2023
82.77
Mar 2024
108.21
Mar 2025
97.7

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.